ADAP News and Press, Adaptimmune Therapeutics plc

2024-07-03 11:11:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For most of the year, biotech has been one of the most explosive sectors on the market. Far from over, further upside is likely, thanks to some of the top biotech stocks with catalysts. ...

2024-07-03 09:54:32 ET Summary Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ...

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma pa...

2024-05-31 16:15:02 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for ADAP on May 31, 2024 02:43PM ET. The previous analyst recommendation was Equal-Weight. ADAP was trading at $1.135 at issue of the analyst recommendation. The overall analyst consensus : BUY...

2024-05-30 17:02:10 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune GA...

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...

2024-05-30 08:00:14 ET George Farmer from Scotiabank issued a price target of $3.15 for ADAP on 2024-05-30 07:11:00. The adjusted price target was set to $3.15. At the time of the announcement, ADAP was trading at $1.01. The overall price target consensus is at $2.33 wit...

2024-05-15 12:53:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adaptimmune Therapeutics (NASDAQ: ADAP ) just reported results for the first quarter of 2024. Adaptimmune Therapeutics reported earnings per share of -18 cents. This was b...

2024-05-15 10:07:03 ET Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Conference Call May 15, 2024, 08:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer Dennis ...

2024-05-15 07:45:41 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics gets $125M in financing from Hercules Capital Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Qu...